Blog
Feedback
schliessen

Filtern

 

Bibliotheken

Logo der Bibliothek

Logo FID Pharmazie PubPharm Discovery System Universitätsbibliothek Braunschweig Institut für Informationssysteme

PPIs and Beyond : A Framework for Managing Anticoagulation-Related Gastrointestinal Bleeding in the Era of COVID-19

Coronavirus disease of 2019 (COVID-19) can be associated with high morbidity and mortality; patients with severe clinical manifestations may develop significant coagulopathy as well as unexpected thromboembolic complications. In response, centers are increasingly treating selected patients with intermediate-dose prophylactic or even therapeutic dose anticoagulation in order to prevent potentially catastrophic thrombotic complications. With this changing practice, the authors suspect that inpatient gastrointestinal consult teams across the country will be frequently managing COVID-19 patients with gastrointestinal bleeding (GIB). In order to reduce potentially avoidable hospital readmissions for GIB while improving patient outcomes, it is imperative to appropriately risk-stratify patients prior to initiation of anticoagulation. In this review, we discuss how to appropriately identify high-risk patients for GIB and how to mitigate GIB risk with proton-pump inhibitor co-therapy, medication reconciliation, and Helicobacter pylori testing and treating in this complex and morbid population

Year of Publication: 2020
Contained in: Digestive diseases and sciences Vol. 65, No. 8 (2020), p. 2181-2186
All journal articles: Search for all articles in this journal
Language: English
Contributors: Patel, Parita | Author
Sengupta, Neil
Full text access:
Electronic availability is being checked...
Links: Full Text (dx.doi.org)
Keywords: Anticoagulation
COVID-19
Gastrointestinal bleeding
Journal Article
Review
Thrombosis
Additional Keywords: *Blood Coagulation Disorders
*Gastrointestinal Hemorrhage
Anticoagulants
Betacoronavirus
Chemoprevention
Coronavirus Infections
Humans
Pandemics
Pneumonia, Viral
Proton Pump Inhibitors
Risk Adjustment
ISSN: 1573-2568
Note: Copyright: From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Notes: Date Completed 31.07.2020
Date Revised 31.07.2020
published: Print
Citation Status MEDLINE
Copyright: From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
PMID:
    32537704
Physical Description: Online-Ressource
ID (e.g. DOI, URN): 10.1007/s10620-020-06408-x
more publication details ...

Associated Publications

  • Associated records are being queried...
more (+)
Internes Format
LEADER 03689nma a2200685 c 4500
001 NLM312066597
003 DE-601
005 20200801213646.0
007 cr uuu---uuuuu
008 200616s2020 000 0 eng d
024 7 |a 10.1007/s10620-020-06408-x  |2 doi 
028 5 2 |a pubmed20n1287.xml 
035 |a (DE-599)NLM32537704 
040 |b ger  |c GBVCP 
041 0 |a eng 
100 1 |a Patel, Parita 
245 1 0 |a PPIs and Beyond  |h Elektronische Ressource  |b A Framework for Managing Anticoagulation-Related Gastrointestinal Bleeding in the Era of COVID-19 
300 |a Online-Ressource 
500 |a Date Completed 31.07.2020 
500 |a Date Revised 31.07.2020 
500 |a published: Print 
500 |a Citation Status MEDLINE 
500 |a Copyright: From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine 
520 |a Coronavirus disease of 2019 (COVID-19) can be associated with high morbidity and mortality; patients with severe clinical manifestations may develop significant coagulopathy as well as unexpected thromboembolic complications. In response, centers are increasingly treating selected patients with intermediate-dose prophylactic or even therapeutic dose anticoagulation in order to prevent potentially catastrophic thrombotic complications. With this changing practice, the authors suspect that inpatient gastrointestinal consult teams across the country will be frequently managing COVID-19 patients with gastrointestinal bleeding (GIB). In order to reduce potentially avoidable hospital readmissions for GIB while improving patient outcomes, it is imperative to appropriately risk-stratify patients prior to initiation of anticoagulation. In this review, we discuss how to appropriately identify high-risk patients for GIB and how to mitigate GIB risk with proton-pump inhibitor co-therapy, medication reconciliation, and Helicobacter pylori testing and treating in this complex and morbid population 
611 2 7 |a Journal Article  |2 gnd 
611 2 7 |a Review  |2 gnd 
653 2 |a Anticoagulants  |6 D000925  |a administration & dosage  |6 Q000008  |a *adverse effects  |6 Q000009 
653 2 |a Betacoronavirus  |6 D000073640  |a isolation & purification  |6 Q000302 
653 2 |a *Blood Coagulation Disorders  |6 D001778  |a prevention & control  |6 Q000517  |a virology  |6 Q000821 
653 2 |a Chemoprevention  |6 D018890  |a methods  |6 Q000379  |a standards  |6 Q000592 
653 2 |a Coronavirus Infections  |6 D018352  |a *blood  |6 Q000097 
653 2 |a *Gastrointestinal Hemorrhage  |6 D006471  |a chemically induced  |6 Q000139  |a prevention & control  |6 Q000517 
653 2 |a Humans  |6 D006801 
653 2 |a Pandemics  |6 D058873 
653 2 |a Pneumonia, Viral  |6 D011024  |a *blood  |6 Q000097 
653 2 |a Proton Pump Inhibitors  |6 D054328  |a *therapeutic use  |6 Q000627 
653 2 |a Risk Adjustment  |6 D020379  |a *methods  |6 Q000379 
655 7 |a Anticoagulation  |2 gnd 
655 7 |a COVID-19  |2 gnd 
655 7 |a Gastrointestinal bleeding  |2 gnd 
655 7 |a Thrombosis  |2 gnd 
655 7 |a Anticoagulants  |2 gnd 
655 7 |a Proton Pump Inhibitors  |2 gnd 
689 0 0 |A f  |a Journal Article 
689 0 1 |A f  |a Review 
689 0 |5 DE-601 
689 1 0 |a Anticoagulation 
689 1 1 |a COVID-19 
689 1 2 |a Gastrointestinal bleeding 
689 1 3 |a Thrombosis 
689 1 |5 DE-601 
689 2 0 |a Anticoagulants 
689 2 1 |a Proton Pump Inhibitors 
689 2 |5 DE-601 
700 1 |a Sengupta, Neil 
773 0 8 |i in  |t Digestive diseases and sciences  |g Vol. 65, No. 8 (2020), p. 2181-2186  |q 65:8<2181-2186  |w (DE-601)NLM000356484  |x 1573-2568 
856 4 1 |u http://dx.doi.org/10.1007/s10620-020-06408-x  |3 Volltext 
912 |a GBV_NLM 
951 |a AR 
952 |d 65  |j 2020  |e 8  |b 31  |c 08  |h 2181-2186